Liposomal Cyclosporine A
Phase 3Small molecule
Liposomal Cyclosporine A is one of 54 small molecule programs targeting Bronchiolitis Obliterans. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Bronchiolitis
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
E-Mycin
AAzurity Pharmaceuticals
Approved
Biaxin
AbbViePhase 3
Singulair
AstraZenecaPhase 3
N-Acetyl Cyteien
SStanford University
Approved
Inomax
MMallinckrodt
Phase 3
Celestone
SSchering-Plough
Phase 3
Verazinc
FFakultas Kedokteran Universitas Indonesia
Phase 3
SYNAGIS
SSwedish Orphan Biovitrum
Phase 3
Zinc Sulphate
IInternational Centre for Diarrhoeal Disease Research, Bangladesh
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bronchiolitis Obliterans2 trials
Bronchiolitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Liposomal Cyclosporine A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZambon SpA